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Abstract:
Case Presentarion:
Hereditary transthyretin amyloidosis is a progressive, fatal disease that generally involves the peripheral nervous system, the autonomic nervous
system, and the heart. It is autosomal dominant with different penetrance depending on the mutation and the genetic background. Many other
missense mutations of the TTR gene may cause the disease. Being an overall rare disease is very rare to observe the condition of homozygosity. In
particular, cases of homozygosity have been described in patients with ATTRV30M and ATTRV122I amyloidosis. In the former, the phenotype
does not seem to be aggravated, having an age of onset and disease course that does not appear to differ from those of heterozygotes, while in the
latter, the onset appears to be earlier.
Conclusion:
We report  the first  case of ATTRE89Q amyloidosis in a patient  that  was homozygous for the E89Q mutation in the TTR gene.  The clinical
phenotype  resulted  in  the  earlier  disease  onset  reported  in  this  form  of  amyloidosis,  suggesting  that  the  homozygous  condition  may  be
prognostically negative.
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1. INTRODUCTION
Hereditary  transthyretin  amyloidosis  (ATTRv)  is  a
progressive, fatal disease that generally involves the peripheral
nervous system, the autonomic nervous system, and the heart
[1]. Andrade made the first description in 1952; since then, for
several  decades,  it  has  been  considered  a  disease  limited  to
Portugal. Later, it has been well documented and has also been
found  to  be  endemic  in  Japan  and  Sweden  and  is  now
considered a worldwide disease [2, 3]. It is transmitted as an
autosomal dominant trait, due to missense mutations in the TTR
gene,  with  V30M mutation  identified  in  most  patients  in  the
endemic  foci.  However,  more  than  one  hundred  and  thirty
other mutations have been described, with varying geographic
distributions and organ involvement [4, 5]. The ATTRV30M
amyloidosis  originally  described  by  Andrade  is  typically
associated  with  sensory-motor  axonal  polyneuropathy,  often
involving  the  autonomic  nervous  system.  Several  other
mutations can determine a similar phenotype [6, 7]. In recent
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years,  many  other  mutations  associated  with  a  cardiac  or  a
mixed phenotype have been identified and described [8].
The diagnostic delay, which was about 3-4 years up to 10
years ago, in recent years is often shorter, probably thanks to
the attention which recently has greatly increased towards this
disease [9]. Indeed, nowadays, drugs that are very effective in
slowing  or  perhaps  even  stopping  the  disease  are  available;
however,  their effectiveness seems to be more evident in the
early stages of the disease [10 - 12]. Life expectancy in untre-
ated patients is nearly 10 years in V30M patients [13], but is
much  shorter  in  patients  with  mutations  that  cause  cardiac
amyloidosis.  In  ATTRI68L  amyloidosis,  in  which  the
phenotype is predominantly cardiac, the survival is only 37%
from the onset of the disease [14, 15].
Many different missense mutations of the TTR gene have
been  described  within  the  same country  or  even  in  the  same
region [5, 6]. The clinical phenotype may be distinct in relation
to  the  mutation  and  other  genetic  factors  that  are  likely  to
determine  a  considerable  clinical  variability  even  in  patients
with the same amino acid substitution [5, 16, 17]. For example,
it  is  well  known  that  the  ATTRV30M  amyloidosis  typically
has an early onset in Portugal and a late-onset in Sweden and
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Japan.  Polymorphism  of  mitochondrial  DNA  may  be  one
underlying  mechanism  of  onset  variation  [18].
As ATTRV30M amyloidosis is the most frequent, there are
several descriptions of homozygous patients for this mutation
in  the  literature.  Despite  this,  the  genotype-phenotype  corre-
lation of this condition is controversial: in some cases, it does
not  appear  to  differ  significantly  from  heterozygosity;  in
others,  it  appears  to  cause  an  early  onset  [19  -  21].  Surpri-
singly, in several cases, a late onset of symptoms and a greater
survival were reported [22]. Peculiarly, ATTRV30M homozy-
gosity  was  associated  with  a  higher  incidence  of  vitreous
opacity [20 - 22], and in Japan with CNS involvement [23].
As far as we know, the only other TTR  mutation already
described in the homozygous condition is V122I. ATTRV122I
amyloidosis  causes  a  predominant  or  exclusively  cardiac
involvement. ATTRV122I homozygosity was associated with
an early age of onset of the disease, as observed in a cohort of
13  patients  [24].  Furthermore,  we  have  recently  described  a
patient that surprisingly has a neuropathic rather than cardiac
phenotype [25].
We describe the first case of ATTRE89Q amyloidosis in a
patient that was homozygous for this mutation.
2. CASE REPORT
The patient reported that at the age of 32 years, he suffered
from  bilateral  carpal  tunnel  syndrome  (CTS),  successfully
treated with surgery. In the next 5 years, he did not present any
symptoms,  but  when  he  was  37  years  old,  he  started  to
complain of dyspnoea on exertion. He reported the appearance
of breathlessness after climbing one floor of stairs, attributable
to  heart  failure  in  the  second  class  of  New  York  Heart
Association  functional  classification  (NYHA).  An  electro-
cardiogram revealed sinus-rhythm and low-voltage of the QRS
complexes. An echocardiogram showed diffuse left ventricular
wall thickness, an interventricular septal wall thickness of 18
mm,  and  increased  atrial  septal  thickness  with  pericardial
effusion.  He  received  a  diagnosis  of  hypertrophic  cardio-
myopathy.
After  symptoms worsened and dyspnoea  became present
even  with  minimal  effort  (NYHA  class  III),  he  underwent  a
heart transplant at the age of 40. Subsequently the transplant,
he  started  taking  anti-rejection  therapy  with  cyclosporine.
When he  was  41  years  old,  he  started  to  complain  of  sexual
disturbances  and,  in  the  following  years,  he  developed  a
progressive  and  severe  autonomic  dysfunction  causing
orthostatic  hypotension  and  constipation  alternating  with
diarrhea.  Symptoms  secondary  to  dysautonomia  have  been
treated with symptomatic medications such as midodrine and
loperamide,  however,  the  compound  autonomic  dysfunction
test  score  [26]  calculated  retrospectively  fell  from  18/20  to
10/20 over a 6-year period. Since the age of 47, he started to
notice burning pain distally in lower limbs and a few months
later, progressive gait disturbances attributed partly to pain and
partly to lack of balance.
At  the  admission  to  our  tertiary  neuromuscular  centre,
neurological examination showed ataxic gait associated with a
positive  Romberg's  maneuver.  Mild  weakness  of  ankle
dorsiflexion  and  toe  extension  (MRC  4)  and  absent  tendon
reflexes. Pinprick was reduced distally up to the knees, while
vibration  sensation  measured  with  the  Rydel-Seiffer  tuning
fork  was  0  at  the  ankles  and  4  at  the  knees.  Pinprick  was
slightly  reduced  in  the  median  nerve  area  of  distribution  on
both sides.  Joint  position sense was normal.  A blood sample
was  taken  for  TTR  analysis,  and  a  neurophysiological
evaluation was planned, but the patient died a few days later
for sudden cardiac death. Unfortunately, a myocardial biopsy
was  not  performed.  However,  the  echocardiographic  images
were strongly suggestive of amyloid heart disease.
We then investigated the family history, discovering that it
was  suggestive  of  heart  disease  of  unidentified  cause.  The
parents  were  apparently  unrelated,  and  they  were  born  in
different  cities,  although from the same geographical  area in
Syracuse. His mother and two brothers died suddenly at the age
of  53,  58,  and  63  years,  respectively.  The  mother  and  one
brother  also  had  symptoms  compatible  with  carpal  tunnel
syndrome  some  years  before  death.  A  genetic  test  for  TTR
revealed  that  he  was  homozygous  for  ATTRE89Q  mutation
(C265G).
3. DISCUSSION
Among  the  genetic  mutations  responsible  for  ATTRv
amyloidosis,  the  E89Q  mutation  is  the  third  most  frequent
worldwide,  in  agreement  with  an  analysis  of  the  THAOS
register  of  2013.  This  mutation  has  been  associated  with  a
mixed phenotype of the disease, characterized by neuropathic,
cardiological,  and  autonomic  involvement  [27].  The
geographical  areas  affected  by  this  mutation  are  mostly
Bulgaria and Italy (Sicily) [28], being in our region the variant
that most often causes ATTRv cardiac amyloidosis [29].
In patients carrying this mutation in Bulgaria, the disease is
characterized  by  differences  in  penetrance  and  age  of  onset
also  within  the  same  family,  for  which  a  role  played  by
regulatory  and  epigenetic  factors  in  the  etiopathogenesis  of
amyloidosis  has  been hypothesized.  In  Bulgaria,  the  average
age  of  onset  is  35-70  years,  with  a  predominantly  nervous
involvement in half of the patients and cardiologic in the other
half [30].
In Italy, instead, a recent study of forty subjects carrier of
this  mutation  showed  how  the  onset  of  the  disease  occurs
during  the  5th-6st  decade  with  neuropathic  disorders
(paraesthesia,  gait,  and  balance  disorders),  carpal  tunnel
syndrome and dysautonomic disorders (orthostatic hypotension
and  constipation/diarrhea),  with  subsequent  appearance  of
heart  failure.  Nevertheless,  instrumental  evaluations  such  as
ECG,  echocardiography,  and  cardiac  scintigraphy  in
asymptomatic  subjects  have  shown  that  cardiac  involvement
precedes neurological and autonomic involvement. The main
cause of death in these patients is heart failure associated with
amyloidosis. The mean age at death was 63 years [5, 31].
To our knowledge, this is the first patient homozygous for
this allele.  This case showed the earliest  onset  of disease we
have ever observed for ATTRE89Q amyloidosis, with an onset
at  32  years  of  age,  with  bilateral  CTS,  followed  by  severe
progressive  cardiomyopathy  five  years  later  that  made
necessary heart transplantation. Severe autonomic involvement
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appeared, later on, followed by sensory-motor polyneuropathy.
Overall, patient survival from onset of cardiac symptoms was
relatively long,  not  showing a more aggressive course of  the
disease  than  that  observed  in  patients  heterozygous  for  this
mutation  [6].  However,  we  must  consider  that  early-onset
probably  favoured  heart  transplantation,  without  which  the
patient's survival would have been reasonably much shorter.
CONCLUSION
The  medical  awareness  of  ATTR  amyloidosis  has
increased over the past years and the medical awareness is now
higher  due  to  the  availability  of  new  innovative  drugs
motivating  neurologists  to  include  the  examination  of  the
transthyretin  gene  in  patients  with  axonal  polyneuropathy  of
unknown cause, especially when associated with carpal tunnel
syndrome or dysautonomia [6, 32]. However, ATTRv cardiac
amyloidosis  is  still  underdiagnosed,  and  the  very  long
diagnostic  delay  of  this  clinical  case  is  proof  of  this.
Cardiologists  should  pay  close  attention  to  the  characteristic
echocardiographic  aspects  suggestive  of  this  form of  cardiac
amyloidosis [29]. In case of suspicion, 99mTc-diphosphonate
imaging  and/or  magnetic  resonance  imaging  with  late
gadolinium should represent the second level exams [33]. TTR
gene analysis must be performed to confirm the diagnosis.
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